| For: | Zhang L, Xue S, Hou J, Chen G, Xu ZG. Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review. World J Diabetes 2020; 11(11): 553-566 [PMID: 33269066 DOI: 10.4239/wjd.v11.i11.553] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v11/i11/553.htm |
| Number | Citing Articles |
| 1 |
Hongli Zhang, Jiewen Chen, Niansong Wang, Wei Chen, Youhua Xu, Dingkun Gui. Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review. Diabetes/Metabolism Research and Reviews 2025; 41(6) doi: 10.1002/dmrr.70077
|
| 2 |
Noorain Ahmad, Harish Veerapalli, Chetan Reddy Lankala, Everardo E Castaneda, Afia Aziz, Amy G Rockferry, Pousette Hamid. Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review . Cureus 2021; doi: 10.7759/cureus.19325
|
| 3 |
Tzu-Hsien Chuang, Hsin-Yen Cho, Sheng-Nan Wu. The Evidence for Sparsentan-Mediated Inhibition of INa and IK(erg): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor. Biomedicines 2021; 10(1) doi: 10.3390/biomedicines10010086
|
| 4 |
Guido Gembillo, Luca Visconti, Valeria Tranchida, Chiara Nardi, Sebastiano Calimeri, Maria Elsa Gambuzza, Maria Princiotto, Chiara Chinigo, Luca Soraci, Domenico Santoro. Evolving strategies for nephroprotection in diabetic kidney disease: From established therapies to novel interventions. World Journal of Diabetes 2026; 17(4): 115058 doi: 10.4239/wjd.v17.i4.115058
Abstract(58) |
Core Tip(63) |
Full Article(HTML)(234)
|
Full Article (PDF)-1376K(141)
|
Full Article with Cover (PDF)-1633K(356)
|
Full Article (XML)-331K(16)
|
Audio-564K(4)
|
Peer-Review Report-251K(20)
|
Answering Reviewers-152K(76)
|
Supplementary Material-501K(16)
|
Times Cited (0)
|
Total Visits (854)
|
Open
|
| 5 |
Semwal Bhupesh, Neha Chauhan, Verma Jyoti, Kumar Ankit, Singh Sonia, Singh Bhupendra. A Narrative Review of Signaling Pathway and Treatment Options for Diabetic Nephropathy. Current Molecular Medicine 2025; 25(2) doi: 10.2174/1566524023666230727093911
|
| 6 |
Muqin Li, Chenyang Xie, Yue Qiu, Xiaoyue Li, Guanjun Han, Ning Ma, Guofeng Wang. Progress in mechanistic and clinical translational research of endothelin A receptor antagonists in the treatment of diabetic kidney disease: a narrative review. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1808445
|
| 7 |
Yang Yang, Gaosi Xu. Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney Disease. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.872918
|
| 8 |
Jingfang Wan, Yilun Shen, Xin Yang, Juan Chen, Yani He, Kehong Chen, Jia Chen. Abnormal lipid metabolism in senescent renal tubular cells in diabetic nephropathy. Cellular and Molecular Life Sciences 2026; 83(1) doi: 10.1007/s00018-026-06199-w
|
| 9 |
Yi Lv, Chen Ye, Zixi Li, Jiajia Ye, Huanhuan Cao, Chun Zhang, Huajun Jiang, Yumei Wang. Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies. Diabetes/Metabolism Research and Reviews 2025; 41(7) doi: 10.1002/dmrr.70098
|
| 10 |
Giovanna Capolongo, Giovambattista Capasso, Davide Viggiano. A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics. International Journal of Molecular Sciences 2022; 23(7) doi: 10.3390/ijms23073915
|
| 11 |
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, Gianpaolo Reboldi. Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection. International Journal of Molecular Sciences 2024; 25(7) doi: 10.3390/ijms25073969
|
| 12 |
Shuhui Yang, Jiankun Deng, Xiaoxu Weng, Zhaojie Ma, Nie Lin, Yili Xiao, Rui Zuo, Yufei Hu, Canbin Zheng, Xiaoshan Zeng, Qimao Lin, Kaijian Hou. Reduced abundance of Fusobacterium signifies cardiovascular benefits of sodium glucose cotransporter 2 inhibitor in type 2 diabetes: a single arm clinical trial. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1600464
|
| 13 |
Olivia Blazek, George L. Bakris. A review of novel endothelin antagonists and overview of non-steroidal mineralocorticoid antagonists for treating resistant hypertension: An update. European Journal of Pharmacology 2024; 979 doi: 10.1016/j.ejphar.2024.176752
|
| 14 |
Jiamian Geng, Sijia Ma, Hui Tang, Chun Zhang. Pathogenesis and Therapeutic Perspectives of Tubular Injury in Diabetic Kidney Disease: An Update. Biomedicines 2025; 13(6) doi: 10.3390/biomedicines13061424
|
| 15 |
Sidhant Verma, Susant Katwal, Harshika Reddy Akula, Alfiya Inamdar, Sarah S Kundukulam, Mariyam Khan, Ahmad Bin Abdul Qayyum Satti, Shweta Menon, Manju Rai. Guideline-Directed Medical Therapy for Diabetic Kidney Disease: Advances in Primary and Secondary Prevention. Cureus 2026; doi: 10.7759/cureus.101867
|
| 16 |
Jiawen Huang, Tangli Xiao, Jun Zhang, Yan Li, Liangyu Yin, Chun Zhou, Shaobo Wang, Jiachuan Xiong, Jinghong Zhao. Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis. Journal of Nephrology 2026; 39(2) doi: 10.1093/joneph/aajaf052
|
| 17 |
Antony Sameh Mansour. Autoregulation: mediators and renin–angiotensin system in diseases and treatments. Future Journal of Pharmaceutical Sciences 2023; 9(1) doi: 10.1186/s43094-023-00482-4
|
| 18 |
Yan Miao, Pan He, Dan-Yu Wang, Lei Yan, Hui-Xia Cao, Feng-Min Shao. Renal and metabolic effects of semaglutide plus canagliflozin <i>vs</i> canagliflozin alone in type 2 diabetic nephropathy. World Journal of Diabetes 2026; 17(2): 112867 doi: 10.4239/wjd.v17.i2.112867
|
| 19 |
Te-Ling Lu, Sheng-Nan Wu. Investigating the Impact of Selective Modulators on the Renin–Angiotensin–Aldosterone System: Unraveling Their Off-Target Perturbations of Transmembrane Ionic Currents. International Journal of Molecular Sciences 2023; 24(18) doi: 10.3390/ijms241814007
|
| 20 |
Katherine R. Tuttle, Rajiv Agarwal, Charles E. Alpers, George L. Bakris, Frank C. Brosius, Peter Kolkhof, Jaime Uribarri. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney International 2022; 102(2) doi: 10.1016/j.kint.2022.05.012
|
| 21 |
Susan Miller, Walter Moos, Barbara Munk, Stephen Munk, Charles Hart, David Spellmeyer. Managing the Drug Discovery Process. 2023; doi: 10.1016/B978-0-12-824304-6.00001-8
|
| 22 |
Pratik Shankar Rakshe, Anil Bhanudas Gaikwad. Diabetic kidney disease: exploring mechanistic depths and the future of pharmacological intervention. Naunyn-Schmiedeberg's Archives of Pharmacology 2026; 399(2) doi: 10.1007/s00210-025-04534-9
|
| 23 |
Kimio Watanabe, Emiko Sato, Eikan Mishima, Mariko Miyazaki, Tetsuhiro Tanaka. What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances. International Journal of Molecular Sciences 2022; 24(1) doi: 10.3390/ijms24010570
|
| 24 |
Wei Huang, Yi-Yuan Chen, Zi-Qi Li, Fang-Fang He, Chun Zhang. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. International Journal of Molecular Sciences 2022; 23(18) doi: 10.3390/ijms231810882
|
| 25 |
Zeinab H. El-Said, Sherihan I. Gouda, Hebatallah A. Mahgoub, S El_desouky, Neven A. Ebrahim. L- Thyroxine ameliorates renal function in thyroidectomized diabetic nephropathy rats through downregulation of TGF- β1, Ang II and ET-1 expression. Egyptian Journal of Basic and Applied Sciences 2023; 10(1) doi: 10.1080/2314808X.2023.2248711
|
| 26 |
Weifang Li, Qiuwang Zhang, Michael J. B. Kutryk. Overexpression of miR-454-3p inhibits high glucose-induced ET-1 expression, leading to eNOS upregulation in endothelial cells: an integrated bioinformatics and experimental analysis. Human Cell 2025; 38(6) doi: 10.1007/s13577-025-01309-5
|